<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04657224</url>
  </required_header>
  <id_info>
    <org_study_id>CR108877</org_study_id>
    <secondary_id>2020-003149-12</secondary_id>
    <secondary_id>64264681LYM1002</secondary_id>
    <nct_id>NCT04657224</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase 1b, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Combination With JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine: the recommended Phase 2 doses (RP2Ds) of&#xD;
      JNJ-64264681 and JNJ 67856633 when administered together in participants with B cell&#xD;
      non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Part A - Dose Escalation);&#xD;
      and the safety of the RP2Ds for this combination in different histologies/participant&#xD;
      populations (Part B - Cohort Expansion).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bruton's tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase that plays a critical role in&#xD;
      B cell activation via the B cell receptor (BCR) signaling pathway. BTK is important for&#xD;
      normal B-cell activation and the pathophysiology of B cell malignancies. A few BTK inhibitors&#xD;
      have demonstrated clinical activity in non-Hodgkin lymphoma (NHL) and chronic lymphocytic&#xD;
      leukemia (CLL). Non-Hodgkin lymphoma represents a diverse set of diseases, of which more than&#xD;
      60 subtypes have been identified and classified by the world health organization.&#xD;
      JNJ-64264681 is a second-generation, orally active, selective, and irreversible covalent&#xD;
      inhibitor of BTK and JNJ-67856633 is an orally bioavailable, potent, and selective first in&#xD;
      class mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor&#xD;
      that binds to an allosteric site on MALT1 with a mixed-type mechanism. JNJ-64264681 and&#xD;
      JNJ-67856633 inhibit BTK and MALT1, respectively, and both BTK and MALT1 are involved in&#xD;
      transmitting the pro-survival BCR signal. The study will consist of Screening Phase (28&#xD;
      days); Treatment Phase (from Cycle 1 Day 1 up to end of treatment, each cycle is a 21-day&#xD;
      cycle) and a Follow-up Phase (from end of treatment visit until lost to follow-up, withdrawal&#xD;
      of consent, death, 6 months after start of first subsequent antineoplastic therapy). The&#xD;
      total study duration is estimated at 2 years and 2 months. Safety assessments will include&#xD;
      physical examinations, vital signs, electrocardiograms, clinical safety laboratory&#xD;
      assessments, eastern cooperative oncology group performance status, echocardiogram, and&#xD;
      adverse events monitoring.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2021</start_date>
  <completion_date type="Anticipated">January 12, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 16, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Number of Participants with Dose-limiting Toxicity (DLT)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Number of participants with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A and Part B: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to 2 years and 3 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of JNJ-64264681 and JNJ-67856633</measure>
    <time_frame>Up to 2 years and 3 months</time_frame>
    <description>Plasma concentrations of JNJ-64264681 and JNJ-67856633 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bruton's Tyrosine Kinase (BTK) Occupancy in Peripheral Blood Mononuclear Cell (PBMCs)</measure>
    <time_frame>Up to 2 years and 3 months</time_frame>
    <description>BTK occupancy will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 2 years and 3 months</time_frame>
    <description>ORR is defined according to Non-Hodgkin Lymphoma, International Workshop on Chronic Lymphocytic Leukemia (iwCLL); and Response assessment in Waldenström Macroglobulinemia (IWWM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Response</measure>
    <time_frame>Up to 2 years and 3 months</time_frame>
    <description>Time to first response defined for the responders as the time from the date of first dose of study treatment to the date of initial documentation of a first response as defined in the disease-specific response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 2 years and 3 months</time_frame>
    <description>DOR will be calculated from the date of initial documentation of a response to the date of first documented evidence of relapse, as defined in the disease-specific response criteria, or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Part A: Dose escalation: JNJ-64264681 and JNJ-67856633</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-64264681 and JNJ-67856633 will be administered together until disease progression, intolerable toxicity, withdrawal of consent, or the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Cohort Expansion: JNJ-64264681 and JNJ-67856633</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-64264681 and JNJ-67856633 at the recommended Phase 2 dose (RP2D) determined in Part 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64264681</intervention_name>
    <description>JNJ-64264681 capsules will be administered orally.</description>
    <arm_group_label>Part A: Dose escalation: JNJ-64264681 and JNJ-67856633</arm_group_label>
    <arm_group_label>Part B: Cohort Expansion: JNJ-64264681 and JNJ-67856633</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-67856633</intervention_name>
    <description>JNJ-67856633 capsules or tablets will be administered orally.</description>
    <arm_group_label>Part A: Dose escalation: JNJ-64264681 and JNJ-67856633</arm_group_label>
    <arm_group_label>Part B: Cohort Expansion: JNJ-64264681 and JNJ-67856633</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1&#xD;
&#xD;
          -  Cardiac parameters within the following range: corrected QT interval (QTcF) &lt;= 480&#xD;
             milliseconds&#xD;
&#xD;
          -  Participants with B cell non-Hodgkin lymphoma (NHL) must have tumor tissue available&#xD;
             at baseline as described in the protocol. This is not required for participants with&#xD;
             chronic lymphocytic leukemia (CLL)&#xD;
&#xD;
          -  Women of childbearing potential must agree to use a barrier method of contraception;&#xD;
             use a highly effective preferably user-independent method of contraception; not to&#xD;
             donate eggs (ova, oocytes) or freeze them for future use for the purposes of assisted&#xD;
             reproduction during the study; not to plan to become pregnant; and not to breast-feed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Part A and select cohorts in Part B: Prior treatment with JNJ 64264681 or&#xD;
             JNJ-67856633. Previously discontinued treatment with a Bruton's tyrosine kinase (BTK)&#xD;
             or mucosa-associated lymphoid tissue lymphoma translocation protein (MALT) inhibitor&#xD;
             other than JNJ 64264681 or JNJ-67856633 due to participant or doctor choice without&#xD;
             evidence of progression or intolerable class-related toxicity will be eligible&#xD;
&#xD;
          -  Known (active) central nervous system (CNS) involvement&#xD;
&#xD;
          -  Received prior solid organ transplantation&#xD;
&#xD;
          -  Participant has known allergies, hypersensitivity, or intolerance to JNJ-64264681 or&#xD;
             JNJ 67856633 or excipients&#xD;
&#xD;
          -  Toxicities from previous anti-cancer therapies that have not resolved to baseline&#xD;
             levels, or to Grade less than (&lt;) 2 (except for alopecia [&gt;=Grade 2], vitiligo [Grade&#xD;
             2] and peripheral neuropathy [Grade 1])&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scientia Clinical Research</name>
      <address>
        <city>Randwick</city>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ St.-Jan Brugge-Oostende AV</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent - UZ GENT</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur - Site Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu Hotel Dieu</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours Cedex 9</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arensia Exploratory Medicine</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky MC</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arensia Exploratory Medicine</name>
      <address>
        <city>Chisinau</city>
        <zip>Md2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pratia Onkologia Katowice</name>
      <address>
        <city>Katowice</city>
        <zip>40-519</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pratia MCM Krakow</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Poznan</name>
      <address>
        <city>Skorzewo</city>
        <zip>60-185</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Vall D Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Fund. Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ARENSIA Exploratory Medicine Unit</name>
      <address>
        <city>Kiev</city>
        <zip>8112</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Trust</name>
      <address>
        <city>Surrey</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Moldova, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108877</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

